Inflammation
Chronic low-grade inflammation — inflammaging — is the silent adversary and Arete's headline efficacy target.
Chronic low-grade inflammation — inflammaging — is Arete's primary biological target, and hsCRP is the headline efficacy marker (Johnson: below detection). IL-6 and TNF-α cytokine panels read deeper; short-chain fatty acids (butyrate) capture the microbiome–inflammation axis; vitamin D modulates immunity. Johnson's 60-session HBOT protocol at 2 ATA wiped systemic inflammation. The core question: does the house's heat exposure correlate with hsCRP reduction across 90 days?
What we track
| Marker | Captures | Target |
|---|---|---|
| hsCRP | Systemic inflammation | Below detection (<0.5 mg/L) |
| IL-6 / TNF-α | Chronic low-grade cytokines | Low, stable |
| Butyrate | Microbiome–inflammation axis | High production |
| Vitamin D (25-OH) | Immune modulation | 40–80 ng/mL |
hsCRP — the headline efficacy marker
Chronic low-grade inflammation — inflammaging — is Arete's primary biological target, and hsCRP is the number we publish against. Johnson's 60-session HBOT protocol at 2 ATA drove his systemic inflammation below detection. The house's question: does sustained heat exposure correlate with hsCRP reduction across 90 days?
The gut connection
Roughly 70% of the body's immune cells live in the gut, and short-chain fatty acids like butyrate shape the cytokine environment — which is why the nourishment zone is an inflammation intervention, not just a refuelling stop.